2. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

PDGFR Tyrosine kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10408
    Ki20227
    4 Publications Verification

    		 c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
    Ki20227
  • HY-112412
    PDGFR Tyrosine kinase-IN-1

    		PDGFR Neurological Disease
    PDGFR Tyrosine kinase-IN-1, a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine kinase-IN-1 can be used for the research of amyotrophic lateral sclerosis .
    PDGFR Tyrosine kinase-IN-1
  • HY-103032
    Multi-kinase inhibitor 1

    		PDGFR c-Kit Bcr-Abl Cancer
    Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
    Multi-kinase inhibitor 1
  • HY-15463S1
    Imatinib-d4

    STI571 d4; CGP-57148B d4

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d4
  • HY-15463S
    Imatinib-d8
    1 Publications Verification

    STI571-d8; CGP-57148B-d8

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d8
  • HY-103032R
    Multi-kinase inhibitor 1 (Standard)

    		Reference Standards PDGFR c-Kit Bcr-Abl Cancer
    Multi-kinase inhibitor 1 (Standard) is the analytical standard of Multi-kinase inhibitor 1 (HY-103032). This product is intended for research and analytical applications. Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
    Multi-kinase inhibitor 1 (Standard)
  • HY-10408R
    Ki20227 (Standard)

    		Reference Standards c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 (Standard) is the analytical standard of Ki20227 (HY-10408). This product is intended for research and analytical applications. Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
    Ki20227 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: